UnitedHealth Group Incorporated (UNH Quick QuoteUNH ) stands well-poised for growth on the back of robust top-line growth, strong presence amid Medicare and Medicaid markets, and a solid financial position. An upbeat 2021 EPS guidance reinstates the growth prospects for the stock.
Zacks Rank & Price Performance
Presently, UnitedHealth Group carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The stock has gained 31.7% over a year compared with the industry’s rally of 23.2%. However, the Zacks Medical sector has lost 2.8% in the said time frame.
Image Source: Zacks Investment Research
Style Score
The company is well-poised for progress as evident from its impressive VGM Score of A. Here V stands for Value, G for Growth and M for Momentum, with the score being a weighted combination of all three factors.
Top Medical Stocks To Watch Right Now: Civista Bancshares, Inc. (CIVB)
CIVISTA BANCSHARES, INC. (“CBI”) was organized under the laws of the State of Ohio on February 19, 1987 and is a registered financial holding company under the Gramm-Leach-Bliley Act of 1999, as amended. CBI’s office is located at 100 East Water Street, Sandusky, Ohio. CBI and its subsidiaries are sometimes referred to together as the Company. The Company had total consolidated assets of $1,315,041 at December 31, 2015.
CIVISTA BANK (“Civista”), owned by the Company since 1987, opened for business in 1884 as The Citizens National Bank. In 1898, Civista was reorganized under Ohio banking law and was known as The Citizens Bank and Trust Company. In 1908, Civista surrendered its trust charter and began operation The Citizens Banking Company. The name Civista Bank was introduced during the first quarter of 2015 to solidify our dual Citizens/Champaign brand and distinguish ourselves from the many other Citizens’ Banks in existing and prospective markets. Advisors’ Opinion:
- [By Logan Wallace]
Lakeland Financial (NASDAQ:LKFN) and Civista Bancshares (NASDAQ:CIVB) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
- [By Max Byerly]
Get a free copy of the Zacks research report on Civista Bancshares (CIVB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Shares of Civista Bancshares Inc (NASDAQ:CIVB) have been given a consensus recommendation of “Hold” by the eight research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $27.00.
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Civista Bancshares (CIVB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top Medical Stocks To Watch Right Now: BioMarin Pharmaceutical Inc.(BMRN)
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The company?s commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis (MPS) VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It develops GALNS, an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-673, a Phase I/II clinical trial product for the treatment of cancer; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of Kuvan and other products containing 6R-BH4 and PEG-PAL for PKU. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in Novato, California.
Advisors’ Opinion:
- [By ]
BioMarin Pharmaceutical (BMRN) rose 4.45% after getting raised to Buy from Hold at Stifel. Analyst Paul Matteis cited the stock’s underperformance, as well as the potential approval of one of its drugs.
- [By ]
Founded in 1996, rare genetic diseases specialist BioMarin (Nasdaq: BMRN) has been around for a while. And it’s been successful, too, with seven products already on the market. One big problem, though — BMRN has not yet managed to break even. But the negative net-income streak is about to end this year, as the company is expected to earn $0.85 per share in 2019 (on $1.7 billion in revenue) and $1.75 next year (on $2 billion of revenue). On the verge of profitability and with a strong pipeline, BMRN also looks good as a potential takeover candidate.
- [By Max Byerly]
Several research analysts recently weighed in on BMRN shares. Oppenheimer dropped their target price on shares of BioMarin Pharmaceutical from $92.00 to $81.00 in a report on Friday, February 22nd. Cowen reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a report on Monday, January 7th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $126.00 target price on shares of BioMarin Pharmaceutical in a report on Monday, January 7th. Wedbush set a $127.00 target price on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a report on Wednesday, November 14th. Finally, SunTrust Banks dropped their target price on shares of BioMarin Pharmaceutical to $117.00 and set a “buy” rating for the company in a report on Monday, February 25th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $112.82.
TRADEMARK VIOLATION WARNING: “Freestone Capital Holdings LLC Buys Shares of 3,798 BioMarin Pharmaceutical Inc. (BMRN)” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at www.tickerreport.com/banking-finance/4203166/freestone-capital-holdings-llc-buys-shares-of-3798-biomarin-pharmaceutical-inc-bmrn.html.
BioMarin Pharmaceutical Company Profile
- [By Brian Orelli]
On the surface, BioMarin Pharmaceutical (NASDAQ:BMRN) looked like it had a rough fourth quarter with revenue down year over year. But dig a little deeper, and the decline appears to be explained by the nature of the company’s business. With new-drug launches off to a good start and a well-stocked late-stage pipeline, there doesn’t appear to be anything wrong with the orphan-drug company.
Top Medical Stocks To Watch Right Now: Public Service Enterprise Group Incorporated(PEG)
We were incorporated under the laws of the State of New Jersey in 1985 and our principal executive offices are located at 80 Park Plaza, Newark, New Jersey 07102. We conduct our business through two direct wholly owned subsidiaries, PSE&G and Power, each of which also has its principal executive offices at 80 Park Plaza, Newark, New Jersey 07102. We are an energy company with a diversified business mix. Our operations are located primarily in the Northeastern and Mid- Atlantic United States. Our business approach focuses on operational excellence, financial strength and disciplined investment. As a holding company, our profitability depends on our subsidiaries’ operating results. Below are descriptions of our two principal direct operating subsidiaries. Advisors’ Opinion:
- [By Stephan Byrd]
Pattern Energy Group Inc (NASDAQ:PEGI) (TSE:PEG) – Investment analysts at Oppenheimer issued their Q1 2019 earnings per share (EPS) estimates for shares of Pattern Energy Group in a report issued on Sunday, March 3rd. Oppenheimer analyst C. Rusch expects that the utilities provider will earn $0.02 per share for the quarter. Oppenheimer also issued estimates for Pattern Energy Group’s Q2 2019 earnings at $0.02 EPS, Q3 2019 earnings at ($0.02) EPS, Q4 2019 earnings at $0.03 EPS, FY2019 earnings at $0.05 EPS and FY2020 earnings at $0.00 EPS.
- [By Logan Wallace]
ILLEGAL ACTIVITY NOTICE: “Blueshift Asset Management LLC Buys Shares of 25,177 Public Service Enterprise Group Inc. (PEG)” was published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at www.tickerreport.com/banking-finance/4200820/blueshift-asset-management-llc-buys-shares-of-25177-public-service-enterprise-group-inc-peg.html.
- [By Shane Hupp]
National Asset Management Inc. decreased its holdings in shares of Public Service Enterprise Group Inc. (NYSE:PEG) by 14.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,445 shares of the utilities provider’s stock after selling 1,449 shares during the quarter. National Asset Management Inc.’s holdings in Public Service Enterprise Group were worth $440,000 as of its most recent SEC filing.
Top Medical Stocks To Watch Right Now: Euronav NV(EURN)
Euronav NV was incorporated under the laws of Belgium on June 26, 2003 for an indefinite term, and we grew out of the combination of certain tanker businesses carried out by three companies that had a strong presence in the shipping industry: Compagnie Maritime Belge NV, or CMB, formed in 1895, Compagnie Nationale de Navigation SA, or CNN, formed in 1938, and Ceres Hellenic Shipping Enterprises Ltd., or Ceres Hellenic, formed in 1950. Our predecessor started doing business under the name “Euronav” in 1989. Our Company has the legal form of a public limited liability company (naamloze vennootschap/société anonyme). Our principal shareholder is Marc Saverys, individually or through Saverco NV, or Saverco, an entity controlled by him. The Saverys family has had a continuous presence in the shipping industry since the early nineteenth century. Advisors’ Opinion:
- [By Stephan Byrd]
Euronav (NYSE:EURN) and TOP SHIPS (NASDAQ:TOPS) are both small-cap transportation companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.
- [By Logan Wallace]
Seanergy Maritime (NASDAQ: SHIP) and Euronav (NYSE:EURN) are both small-cap transportation companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.
- [By Lisa Levin]
Check out these big penny stock gainers and losers
Losers
Teradyne, Inc. (NYSE: TER) fell 10.8 percent to $37.02 in pre-market trading after the company issued downbeat Q2 guidance.
Edwards Lifesciences Corporation (NYSE: EW) fell 9.2 percent to $122.29 in pre-market trading. Edwards Lifesciences reported better-than-expected results for its first quarter, but issued weak earnings guidance for the second quarter.
New Gold Inc. (NYSE: NGD) fell 8.8 percent to $2.30 in pre-market trading after rising 4.13 percent on Tuesday.
Gold Fields Limited (ADR) (NYSE: GFI) fell 8.6 percent to $3.61 in pre-market trading.
Natus Medical Incorporated (NASDAQ: BABY) fell 8.2 percent to $32.95 in pre-market trading after the company issued weak forecast for the second quarter.
Atossa Genetics Inc. (NASDAQ: ATOS) shares fell 7.9 percent to $3.50 in pre-market trading after climbing 27.09 percent on Tuesday.
Bright Scholar Education Holdings Limited (NYSE: BEDU) shares fell 6.7 percent to $13.58 in pre-market trading after reporting Q1 results.
Sangamo Therapeutics Inc (NASDAQ: SGMO) fell 5.9 percent to $16.75 in pre-market trading following announcement of a $200 million common stock offering.
Foresight Autonomous Holdings Ltd (NASDAQ: FRSX) shares fell 5.7 percent to $3.29 in pre-market trading after declining 3.32 percent on Tuesday.
Euronav NV (NYSE: EURN) fell 4.8 percent to $8.40 in pre-market trading.
Limelight Networks, Inc. (NASDAQ: LLNW) shares fell 4.3 percent to $4.69 in pre-market trading.
Gaming and Leisure Properties Inc (NASDAQ: GLPI) shares fell 4.1 percent to $32.92 in pre-market trading after the company issued downbeat quarterly results and reported the retirement of CFO William Clifford
Top Medical Stocks To Watch Right Now: China TechFaith Wireless Communication Technology Limited(CNTF)
China Techfaith Wireless Communication Technology Limited, incorporated on June 25, 2004, is a developer, owner and operator of commercial real estate properties across China, as well as China-based mobile solutions provider for the global mobile handsets market. The Company’s segments include Mobile phone business and Real estate business. The Company focuses on the original design and development of specialized mobile handsets under its customer’s brands and its own brands for consumers and enterprises, and the sales of finished products to its local and international customers.
Mobile phone business
The Company provides primary types of products to its customers, including feature phones, smart phones, wireless modules and data cards, other components, such as printed circuit board assemblies, as well as wireless software and applications. The Company provides supervisory and technical support to electronic manufacturing services (EMS) providers. Its EMS providers engage in assembly and manufacturing operations and offer testing services of the assembled printed circuit boards, systems and subsystems. The Company offers Mobile Handset Design Services based on Existing Platforms to design a new model of mobile handset based on its existing design platform. The Company’s Successor Model Design Services allows designing a successor model of an existing customer’s mobile handset previously designed by it to incorporate additional functions and/or industrial design. Its Mobile Handset Design Services Based on New Platforms allows designing a new model of mobile handset based on a new design platform specified by the customer.
Real estate business
The Company buys office building and acquires land use. The Company acquires land use right, finance real estate deals, build projects, create, imagine, control and orchestrate the process of development from the beginning to end. The Company’s activities range from construction, renovation and re-lease of existing buildings to purchase of raw land and the sale of existing buildings.
The Company competes with Sim Technology Group Limited, BYD Electronics Limited, Longcheer Holdings Limited, Seal Technologies Limited, Apple, Samsung, ZTE, Huawei, Lenovo, Xiaomi, Wanda Group, Capital Land, R&F Properties and Soho China.
Advisors’ Opinion:
- [By Max Byerly]
eXp World (NASDAQ:EXPI) and China Techfaith Wireless Comm. Tech. (NASDAQ:CNTF) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
Top Medical Stocks To Watch Right Now: Glacier Bancorp, Inc.(GBCI)
Glacier Bancorp, Inc. (“Company”), headquartered in Kalispell, Montana, is a Montana corporation incorporated in 2004 as a successor corporation to the Delaware corporation originally incorporated in 1990. The Company is a publicly-traded company and its common stock trades on the NASDAQ Global Select Market under the symbol GBCI. The Company provides commercial banking services from 144 locations in Montana, Idaho, Wyoming, Colorado, Utah and Washington through its wholly-owned bank subsidiary, Glacier Bank (“Bank”). The Company offers a wide range of banking products and services, including transaction and savings deposits, real estate, commercial, agriculture, and consumer loans and mortgage origination services. The Company serves individuals, small to medium-sized businesses, community organizations and public entities. For information regarding the Company’s lending, investment and funding activities, see “Item 7. Advisors’ Opinion:
- [By Logan Wallace]
Get a free copy of the Zacks research report on Glacier Bancorp (GBCI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Glacier Bancorp, Inc. (NASDAQ:GBCI) has been assigned an average recommendation of “Hold” from the eight research firms that are currently covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $43.50.
- [By Logan Wallace]
News articles about Glacier Bancorp (NASDAQ:GBCI) have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Glacier Bancorp earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media headlines about the bank an impact score of 46.4959679542028 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Glacier Bancorp (GBCI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
